{"title":"Addressing the Blind Spots of Deaminase Base Editors with CRISPR-Cas Glycosylase-Based Editors.","authors":"Jian Zhou","doi":"10.1177/25731599261475668","DOIUrl":null,"url":null,"abstract":"<p><p>The emergence of CRISPR base editors signifies a pivotal shift in genome editing, moving beyond the \"cut-and-paste\" approach into an era of precise \"chemical rewriting.\" While early editors including CBEs and ABEs enabled efficient base transitions by combining deaminases with Cas9 nickase, their core mechanism limited their application to transition mutations, leaving nearly half of disease-causing transversions unresolved. This review outlines the transformation of DNA glycosylases from unwanted side-effect generators into core drivers of base editor evolution. Through strategic protein engineering, glycosylases have been harnessed to create novel editors that mediate crucial transversion edits, substantially expanding the targeting landscape of precision genome editing. We will examine how these engineered glycosylases achieve programmable DNA rewriting through redirected DNA repair pathways, compare emerging and conventional editors, and explore applications in genetic therapy and functional genomics while addressing ongoing challenges in specificity and delivery. Finally, we envision next-generation editors equipped with artificial intelligence-designed glycosylases capable of spatiotemporally controlled genome manipulation.</p>","PeriodicalId":54232,"journal":{"name":"CRISPR Journal","volume":" ","pages":"25731599261475668"},"PeriodicalIF":3.6000,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CRISPR Journal","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1177/25731599261475668","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
The emergence of CRISPR base editors signifies a pivotal shift in genome editing, moving beyond the "cut-and-paste" approach into an era of precise "chemical rewriting." While early editors including CBEs and ABEs enabled efficient base transitions by combining deaminases with Cas9 nickase, their core mechanism limited their application to transition mutations, leaving nearly half of disease-causing transversions unresolved. This review outlines the transformation of DNA glycosylases from unwanted side-effect generators into core drivers of base editor evolution. Through strategic protein engineering, glycosylases have been harnessed to create novel editors that mediate crucial transversion edits, substantially expanding the targeting landscape of precision genome editing. We will examine how these engineered glycosylases achieve programmable DNA rewriting through redirected DNA repair pathways, compare emerging and conventional editors, and explore applications in genetic therapy and functional genomics while addressing ongoing challenges in specificity and delivery. Finally, we envision next-generation editors equipped with artificial intelligence-designed glycosylases capable of spatiotemporally controlled genome manipulation.
CRISPR JournalBiochemistry, Genetics and Molecular Biology-Biotechnology
CiteScore
6.30
自引率
2.70%
发文量
76
期刊介绍:
In recognition of this extraordinary scientific and technological era, Mary Ann Liebert, Inc., publishers recently announced the creation of The CRISPR Journal -- an international, multidisciplinary peer-reviewed journal publishing outstanding research on the myriad applications and underlying technology of CRISPR.
Debuting in 2018, The CRISPR Journal will be published online and in print with flexible open access options, providing a high-profile venue for groundbreaking research, as well as lively and provocative commentary, analysis, and debate. The CRISPR Journal adds an exciting and dynamic component to the Mary Ann Liebert, Inc. portfolio, which includes GEN (Genetic Engineering & Biotechnology News) and more than 80 leading peer-reviewed journals.